Cystathionine gamma-lyase of perivascular adipose tissue with reversed regulatory effect in diabetic rat artery

Radoslava Emilova, Daniela Dimitrova, Mitko Mladenov, Teodora Daneva, Rudolf Schubert, and Hristo Gagova

The aim of this study is to reveal the regulatory role of cystathionine gamma-lyase (CSE), the main source of hydrogen sulphide (H\textsubscript{2}S) in perivascular adipose tissue (PVAT), of diabetic rats. Diabetes was induced in male rats by a single intraperitoneal injection of streptozotocin. Animals with glucose levels above 20 mmol/L were determined as diabetic. The rat gracilis arteries (a. gracilis) were dissected with or without PVAT. In all \textit{in vitro} experiments endothelium-denuded preparations were used for isometric contraction measurements. Increasing concentrations of 5-hydroxytryptamine (5-HT) from $10^{-15}$ to $10^{-5}$ mol/L were applied to induce gradual increase in force of contractions of circular artery segments. The relaxing effect of CSE was inhibited by DL-propargyl glycine (PGG). The presence of PVAT decreases the contractile response to 5-HT of a. gracilis from control rats. This response is reversed in contraction studies in the same rat artery from diabetic rats. DL-PPG (1 mmol/L) induced significant increase of the force of contraction in artery preparations with PVAT from control rats in the whole range of 5-HT. In contrast, PGG had a relaxing effect in high concentrations of 5-HT (10\textsuperscript{-6} and 10\textsuperscript{-5} mol/L) in diabetic rat arteries with PVAT. It is concluded that in skeletal muscle artery from diabetic rats, a mediator related to H\textsubscript{2}S is released from PVAT. This paracrine mediator increases the maximal force of contraction of endothelium-denuded preparations at higher concentrations of 5-HT.

\textbf{Keywords:} 5-hydroxytryptamine (serotonin); arterial contraction; vascular dysfunction; hydrogen sulphide; diabetes

\textbf{Introduction}

Adipose tissue is the largest endocrine organ, producing various adipokines and many other substances.\cite{1} Perivascular fat, or perivascular adipose tissue (PVAT) is a thin sheet, generated during the embryonic development, which consists of adipocytes and stromal cells, including fibroblasts, leukocytes, stem cells and capillaries.\cite{2} Almost all blood vessels are surrounded by variable amounts of PVAT associated with small arteries and arterioles.\cite{3} PVAT together with vascular endothelium and axonal varicosities of sympathetic neurons in the adventitia, play important role in controlling the contraction of visceral [4] and skeletal muscle arteries.\cite{5}

In this study, we focused on the effects of PVAT in diabetic rat arteries. It is well known that regulators derived from PVAT can stimulate both vasorelaxation and vasoconstriction.\cite{6–8} Therefore, factors secreted from PVAT, like free fatty acids, adipokines, growth factors and others can directly affect the vascular function.\cite{9} However, the rate of excretion of various adipokines may vary between PVAT at different sites in the vascular tree and between PVAT and other adipose tissue depots.\cite{10} The role of PVAT in the regulation of blood vessels depends on metabolic state, inflammation and clinical risk factors. In health, the protective and vasorelaxant properties of the PVAT dominate, while in pathology the pathogenic influences are more evident.\cite{11} PVAT is expanded in obesity and diabetes. This expansion does not only involve enlargement of fat cells, but also acquires macrophages of a more inflammatory phenotype.\cite{12} Cardiovascular dysfunction is one of the complications associated with diabetes, as well as with obesity and the metabolic syndrome.\cite{13} In mesenteric arteries, PVAT was shown to enhance constriction induced by nerve stimulation, an effect mediated by angiotensin II.\cite{14} whereas leptin causes vasodilatation in aortic rings from Wistar-Kyoto (WKY) rats.\cite{15} Besides vasorelaxation by PVAT of the aorta was the first vasoactive effect reported for PVAT, leading to the proposed release of an ADRF (adventitia derived relaxing factor) \cite{7,8,16} identified as hydrogen sulphide (H\textsubscript{2}S).\cite{17} Thus, H\textsubscript{2}S is the third important gas transmitter in mammals, particularly in the...
central nervous and the circulatory systems.[18,19] H2S, derived from adipocytes, is synthesized in cytosol by cystathionine γ-lyase (CSE), using l-cysteine as substrate. [20] H2S exerts artery relaxation mainly by activation of voltage-gated potassium channels, KCNQ type, also known as Kv7 [21,22] and KATP channels.[19] KCNQ channels regulate excitability of smooth muscle cells.[23] Abnormal metabolism and functions of the CSE/H2S pathway have been linked to atherosclerosis and hypertension.[24] CSE knockout mice express hypertension confirming that H2S regulate blood pressure,[25] while substitution of H2S protects against the development of endothelial dysfunction.[26,27] Therefore, paracrine H2S signalling into the artery wall may represent a potential therapeutic target for obesity- and diabetes-associated cardiovascular dysfunction.[28] The data produced in the field can be divided into two main groups: (1) data obtained using an exogenous sources of H2S and (2) data obtained by stimulating endogenous H2S production by using the substrate L-cysteine or through targeting CSE, or by generating H2S from non-enzymatic reactions.[29] For example, the isolation of H2S-releasing and vasoactive substances from garlic may serve as a proposal of novel drugs.[30–32] Furthermore, lipophilic statins (atorvastatin) augment the vasodilatory effect of PVAT by stimulating the H2S production. This effect is mediated by statin-induced ubiquinone (coenzyme Q) depletion, which compromises mitochondrial H2S oxidation.[33] Also, under conditions of reduced H2S release from PVAT, its effects can be mimicked by synthetic KCNQ channel openers.[5] All these findings require to clarify the mechanisms of CSE-dependent regulation of PVAT in health and especially under different pathological conditions.

Therefore, the aim of our study is to reveal the regulatory role of CSE in PVAT of diabetic rat model.

Materials and methods

Study design

In this study, we used two different types of preparations of rat artery gracilis – with and without PVAT (±PVAT) – under three different conditions to explore PVAT regulatory influence. The relaxing effect of CSE was inhibited by 1 mmol/L DL-propargyl glycine (PGG) (Figure 1).

![Figure 1. Experimental protocol.](Image)

Experimental animals and induction of diabetes mellitus

Diabetes was induced in male rats by a single intraperitoneal injection of streptozotocin (STZ, 80 mg/kg body weight). STZ solution (in citrate buffer, pH 4.5) was prepared immediately prior use. Blood glucose levels for all the animals were determined by a glucometer (Gluco Chekâ"®- Rapid Diagnostic PVT.Ltd., Delhi, India) at the first week after the induction and again just prior the experiments. Animals with glucose levels above 20 mmol/L were determined as diabetic.

Measurement of isometric tension in rat artery gracilis

Male rats (200–300 g) were sacrificed under ether at five weeks after treatment for the induction of diabetes. The gracilis arteries (a. gracilis) were dissected and immediately transferred to cold (4 °C) physiological salt solution (PSS). The low temperature ensures the artery to be relaxed during the mounting procedure. For our research, approximately 2 mm vessel segments were selected. PVAT and connective tissue of these preparations were either removed or left intact. We used two groups of preparations from healthy male rats. They were prepared according to the same protocol as the diabetic. Then, half of them were incubated in PSS with 20 mmol/L D-glucose to evaluate the effect of hyperglycaemia. The others were kept in PSS with 5.5 mmol/L D-glucose. Before experiments with vessel rings, the normalization procedure was performed. The aim was to stretch the segment according to normal transmural pressure to ensure optimal response of the preparations. For small arteries, the target transmural pressure is 13.3 kPa. The contractile force was registered by Myodag 2.02 software (Danish Myo Technology A/S, Aarhus, Denmark).

In all in vitro experiments endothelium-denuded preparations were used. The endothelium was removed by gently rubbing the internal surface of the vessel segments with a rat whisker. The absence of endothelium was confirmed by the lack of relaxation to acetylcholine of 60 mmol/L KCl-contracted arteries. All drugs and salts were from Sigma-Aldrich (St. Louis, MO, USA).

The isometric contractions were measured with Small Vessel Myograph (DMT 410M, Aarhus, Denmark). The organ bath was filled with PSS containing (in mmol/L): 119 NaCl, 4.7 KCl, 1.2 KH2PO4, 25 NaHCO3, 1.2 Mg2SO4, 1.6 CaCl2, 20 or 5.5 glucose. The bath solution was continuously oxygenated with a gas mixture of 95% O2 and 5% CO2, and kept at 37 °C; pH = 7.4. After 1 h of equilibration, the contractile force was measured under isometric conditions. The arterial contraction was expressed as a percentage of 60 mmol/L KCl-induced contraction. Increasing concentrations of serotonin from 10−10 to 10−5 mol/L were applied to induce gradual
constriction of circular artery segments. All drugs were added into the bath solution (PSS).

**Statistical analysis**

All data analysis were performed using statistical software SPSS 16.0. All results are given as means ± S.E.M of six separate experiments. Statistical significance was determined using Student t-test to assess significance between two groups or analysis of variance (ANOVA). A value of $p < 0.05$ was considered statistically significant.

**Results and discussion**

Increasing concentrations of serotonin from $10^{-10}$ to $10^{-5}$ mol/L dose dependently enhance the force of contraction of all a. gracilis preparations in the three studied states.

In the presence of a physiological glucose concentration, the 5-hydroxytryptamine (5-HT)-induced contractions of arteries with intact adipose tissue were significantly smaller at $10^{-8}$, $10^{-7}$ mol/L 5-HT ($p < 0.001$) and at $10^{-6}$ mol/L 5-HT ($p < 0.01$) if compared to those without PVAT (data not shown). This result consists with the data from other authors.[1,5] Similar sensitivity to 5-HT of artery rings with and without PVAT was observed when *in vitro* a. gracilis preparations were incubated in hyperglycemic conditions (Figure 2(A)). It is suggested that high glucose conditions has no influence on a. gracilis contraction. Vessel rings with or without intact PVAT of diabetic rats responded with equal contractions to 5-HT when applied in concentrations from $10^{-10}$ to $10^{-7}$ mol/L (n/s). However, at the highest studied concentrations of 5-HT, the preparations with PVAT contracted significantly stronger than those without PVAT (Figure 2(B)). These data suggest different regulatory role of PVAT in diabetic rats if compared to health controls, as well as the release of another mediator that increases the force of contraction of skeletal artery smooth muscle cells in diabetes.

When analysed the responses of blood vessels with PVAT in the three studied states, it was established that preparations from healthy rats in 5.5 mmol/L glucose and 20 mmol/L glucose were not significantly different (n/s), but diabetic rat arteries aroused significantly stronger serotonin-induced contraction ($p < 0.01$). The same results were observed when all the three groups of preparations without PVAT were compared. In control rats, the contractile effect of serotonin remained statistically unchanged in either normal or hyperglycaemic conditions (n/s). However, 5-HT contracted arterial rings of diabetic rats strongly in comparison to the controls.

This difference could be explained with decreased levels of H2S as a result of induction of diabetes. Thus, Whiteman et al. [34] and Jain et al. [35] reported that diabetes is associated with lower circulating levels of H2S. It is also known that rats with STZ-induced diabetes exhibit a decrease in their blood H2S concentrations without any change in the tissue expression of CSE.[36] In a further research, we applied PGG to block H2S synthesis.[25] The addition of a selective inhibitor of CSE – PGG – caused a vast increase of the force of contraction of diabetic a. gracilis in the whole range of 5-HT-induced contractions in all preparations. In these from healthy rats the relaxant effect of adipose tissue was diminished. In the presence of 1 mmol/L PGG, there were no significant differences between arterial responses to 5-HT in the three tested conditions (data not shown).

In the presence of PGG, added to block CSE, the increasing concentrations of 5-HT in the range from $10^{-9}$ to $10^{-7}$ mol/L, a. gracilis, similarly to that from healthy animals, expressed stronger contraction if compared to those without PVAT (data not shown) (Figure 3(A)). In contrast, in the presence PGG, at $10^{-7}$ mol/L 5-HT, the difference between PVAT-containing and PVAT-free
preparations was negligible while above that value of 5-HT diabetic a. gracilis with PVAT responded with lower force of contractions ($10^{-6}$ and $10^{-5}$ mol/l, Figure 3(B)). It is suggested that a second mediator causing vasoconstriction and related to H$_2$S is released (probably produced only in its presence) in a. gracilis preparations with PVAT, isolated from diabetic rats. Its effect reverses the H$_2$S dilatory influence and thus dominates as a common signal molecule at higher 5-HT concentrations. An alternative explanation of these surprising data is that the blockade of H$_2$S production induces the generation of another relaxing mediator from PVAT under the same conditions.

**Conclusions**

The presence of PVAT equally reduces the contractile response to 5-HT of a. gracilis of control animals in normal and hyperglycemic conditions. This response is converted in constriction when the same rat artery is isolated from STZ diabetic rats. The data from this study suggest that PVAT of skeletal muscle artery from diabetic rats releases a contractile mediator related to H$_2$S. The nature of this signal molecule as well as the mechanism of its paracrine regulation and tissue specificity needs further elucidation. The reveal of this PVAT-smooth muscle crosstalk in the artery wall may constitute a therapeutic approach against the harmful effects of diabetes in different vascular beds.

**Funding**

This study was supported by Sofia University St. Kliment Ohridski, Sofia, Bulgaria [grant number 24/2013]; Ministry of Education and Science, Bulgaria Project BG [grant number 051PO001-3.3.05-0001], ‘Science and Business’ [grant number 2-680/12.07.2013].

**References**

[1] Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol. 2012;165(3):643–658.

[2] Takaoka M, Suzuki H, Shioda S, Sekikawa K, Saito Y, Nagai R, Masatuka S. Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue. Arterioscler Thromb Vasc Biol. 2010;30(8):1576–1578.

[3] Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinological Investig. 2002;25(10):823–835.

[4] Gollasch M, Dubrovskova G. Paracrine role for periadventitial adipose tissue in the regulation of arterial tone. Trends Pharmacol Sci. 2004;25(12):647–653.

[5] Zavaritskaya O, Zhuravleva N, Schleifenbaum J, Gloc T, Devermann L, Kluge R, Mladenov M, Gagov H, Fësës G, Gollasch M, Schubert R. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. Hypertension. 2013;61(1):151–159.

[6] Gao YJ, Takemori K, Su LY, Ans WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res. 2006;71(2):363–373.

[7] Gao YJ, Zeng ZH, Teoh K, Sharma AM, Abouzahr L, Cybulsky I, Lamy A, Semelhago L, Lee RM. Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. J Thorac Cardiovasc Surg. 2005;130(4):1130–1136.

[8] Lohn M, Dubrovskova G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002;16:1057–1063.

[9] Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res. 2007;75(4):690–701.

[10] Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104(4):541–549.

[11] Guzik T, Mangulat D, Korbut R. Adipocytokines – novel link between inflammation and vascular function? J Physiol Pharmacol. 2007;54:505–528.
[12] Eringa EC, Bakker W, van Hinsbergh VWM. Paracrine regulation of vascular tone, inflammation and insulin sensitivity by perivascular adipose tissue. Vasc Pharmacol. 2012;56:204–209.

[13] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JL, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–1645.

[14] Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol. 2010;634(1–3):107–112.

[15] Gálvez-Prieto B, Somoza B, Gil-Ortega M, García-Prieto CF, de Las Heras AI, González MC, Arribas S, Aranguez I, Bollbrinker J, Kreutz R, Ruiz-Gayo M, Fernández-Alfonso MS. Anticontractile effect of perivascular adipose tissue and leptin are reduced in hypertension. Front Pharmacol. 2012;3:103.

[16] Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, Gollasch M. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension. 2004;44:271–276.

[17] Fang L, Zhao J, Chen Y, Xu G, Tang C, Liu X, Geng B. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens. 2009;27(11):2174–2185.

[18] Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and inflammation – a tale of three gases. Pharm Ther. 2009;123:386–400.

[19] Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001;20(21):6008–6016.

[20] Kimura H. Hydrogen sulfide: its production, release and functions. Amino Acids. 2011;41(1):113–121.

[21] Kohn C, Schleifenbaum J, Szijártó IA, Markó L, Dubrovská G, Huang Y, Gollasch M. Differential effects of cystathionine-γ-lyase-dependent vasodilatory H2S in periadventitial vasoregulation of rat and mouse aortas. PLoS ONE 2012;7(8):e41951.

[22] Schleifenbaum J, Kohn C, Voblova N, Dubrovská G, Zavarizskaya O, Gloe T, Crean CS, Luft FC, Huang Y, Schubert R, Gollasch M. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28(9):1875–1882.

[23] Soldovieri MV, Miceli F, Taglialetela M. Driving with no brakes: molecular pathophysiology of Kv7 potassium channels. Physiology. 2011;26(5):365–376.

[24] Yang G, Wu L, Bryan S, Khaper N, Mani S, Wang R. Cystathionine gamma-lyase deficiency and overproliferation of smooth muscle cells. Cardiovasc Res. 2010;86:487–495.

[25] Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, Wang R. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587–590.

[26] Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917–935.

[27] Wagner CA. Hydrogen sulfide: a new gaseous signal molecule and blood pressure regulator. J Nephrol. 2009;22(2):173–176.

[28] Sivarajah A, McDonald MC, Thiemermann C. The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. Shock. 2006;26(2):154–161.

[29] Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010;159(6):1236–1246.

[30] Asdaq SM, Inamdar MN. Potential of garlic and its active constituent, S-allyl cysteine, as a hypotensive and cardioprotective in presence of captoprill. Phytotherapy. 2010;18:1016–1026.

[31] Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders: a review. Nutr J. 2002;1:4.

[32] Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller JE, Kraus DW. Hydrogen sulfide mediates the vasoreactivity of garlic. Proc Natl Acad Sci USA. 2007;104(46):17977–17982.

[33] Wojcicka G, Jamroz-Wisniewska A, Atanasova P, Chaldakov GN, Chylińska-Kula B, Beltowski J. Differential effects of statins on endogenous H2S formation in perivascular adipose tissue. Pharmacol Res. 2011;63:68–76.

[34] Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, Tooke JE, Shore AC. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia. 2010;53(8):1722–1726.

[35] Jain SK, Bull R, Rains JL, Bass PF, Levine SN, Reddy S, McVie R, Bocchini JA. Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation? Antioxid Redox Signal. 2010;12(11):1333–1337.

[36] Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gerő D, Szolczezy P, Chang T, Zhou Z, Wu L, Wang R, Papapetroulos A, Szabo C. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci USA. 2011;108(33):13829–13834.